A detailed history of Vanguard Group Inc transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,148,714 shares of VERA stock, worth $81.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,148,714
Previous 1,633,608 31.53%
Holding current value
$81.6 Million
Previous $25.1 Million 268.78%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$14.91 - $49.14 $7.68 Million - $25.3 Million
515,106 Added 31.53%
2,148,714 $92.7 Million
Q4 2023

Feb 14, 2024

BUY
$9.29 - $16.0 $550,135 - $947,488
59,218 Added 3.76%
1,633,608 $25.1 Million
Q3 2023

Nov 14, 2023

BUY
$13.71 - $19.64 $1.84 Million - $2.63 Million
134,125 Added 9.31%
1,574,390 $21.6 Million
Q2 2023

Aug 14, 2023

BUY
$6.11 - $17.83 $277,479 - $809,731
45,414 Added 3.26%
1,440,265 $23.1 Million
Q1 2023

May 15, 2023

BUY
$5.41 - $18.3 $3.39 Million - $11.5 Million
627,318 Added 81.73%
1,394,851 $10.8 Million
Q4 2022

Feb 10, 2023

BUY
$15.74 - $22.19 $136,953 - $193,075
8,701 Added 1.15%
767,533 $14.9 Million
Q3 2022

Nov 14, 2022

BUY
$13.27 - $22.31 $1.09 Million - $1.83 Million
81,895 Added 12.1%
758,832 $16.2 Million
Q2 2022

Aug 12, 2022

BUY
$12.82 - $23.4 $755,533 - $1.38 Million
58,934 Added 9.54%
676,937 $9.21 Million
Q1 2022

May 13, 2022

BUY
$17.8 - $28.06 $4.08 Million - $6.43 Million
229,025 Added 58.88%
618,003 $14.5 Million
Q4 2021

Feb 14, 2022

BUY
$15.01 - $35.8 $2.15 Million - $5.12 Million
143,143 Added 58.23%
388,978 $10.4 Million
Q3 2021

Nov 12, 2021

BUY
$13.71 - $30.6 $2.65 Million - $5.92 Million
193,567 Added 370.34%
245,835 $4.27 Million
Q2 2021

Aug 13, 2021

BUY
$11.5 - $19.97 $601,082 - $1.04 Million
52,268 New
52,268 $693,000

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.03B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.